Faruqi & Faruqi, LLP, a prominent national securities law firm, is investigating potential claims on behalf of investors in Jasper Therapeutics, Inc. Those who purchased or acquired securities between November 30, 2023, and July 3, 2025, are encouraged to contact the firm for guidance on their legal options. The deadline to seek the role of lead plaintiff in a federal securities class action against Jasper is November 18, 2025.
The law firm, which has offices across New York, Pennsylvania, California, and Georgia, is known for recovering hundreds of millions of dollars for investors since its establishment in 1995. According to James (Josh) Wilson, a partner at Faruqi & Faruqi, investors who suffered losses should reach out directly for assistance at 877-247-4292 or 212-983-9330 (Ext. 1310).
The investigation focuses on allegations that Jasper and its executives violated federal securities laws by making false or misleading statements. The complaint claims that Jasper lacked adequate controls to ensure that third-party manufacturers complied with current Good Manufacturing Practices (cGMP), which are essential for producing products suitable for clinical trials. This deficiency reportedly increased the risk of confounding results in ongoing studies, potentially undermining the regulatory and commercial prospects of Jasper’s products, particularly its drug, briquilimab.
On July 7, 2025, Jasper released updated data from the BEACON Study, revealing significant concerns. The company noted that results from specific dosage cohorts were confounded by issues with a particular drug product lot. Ten out of thirteen patients in these cohorts were treated with the affected lot. Jasper is currently investigating this issue and expects to report findings in the coming weeks.
Additionally, the company announced that it would halt the ETESIAN Study and pause the development of briquilimab for asthma, citing a need to refocus resources. This announcement contradicted prior statements about maintaining a robust financial position. Jasper revealed plans for cost-cutting measures, including a potential restructuring, to extend its financial runway and reduce expenses.
Following this news, Jasper’s stock price plummeted by $3.73 per share, a dramatic 55.1% drop, closing at $3.04 on the same day.
In a class action, the court-appointed lead plaintiff is typically the investor with the largest financial interest in the outcome and who also represents the interests of the class. Individuals wishing to be lead plaintiffs can file a motion through their legal counsel, although participation as a lead plaintiff is not necessary to be included in any potential recovery.
Faruqi & Faruqi, LLP is also reaching out to anyone with relevant information regarding Jasper’s actions, including whistleblowers, former employees, and shareholders, to assist in the investigation. For more details about the class action concerning Jasper Therapeutics, interested parties can visit the firm’s website or contact Josh Wilson directly.
As the legal landscape continues to develop, investors are advised to stay informed and consider their options carefully.
